Predicted protein targets (top 15)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | GLP1R | P43220 | 8/20 | 0.41 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.38 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.38 |
| ▸ | HIF1A | Q16665 | 1/20 | 0.38 |
| ▸ | PAOX | Q6QHF9 | 2/20 | 0.36 |
| ▸ | DPP7 | Q9UHL4 | 1/20 | 0.35 |
| ▸ | MEN1 | O00255 | 1/20 | 0.35 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.35 |
| ▸ | FAAH | O00519 | 1/20 | 0.35 |
| ▸ | GNAI3 | P08754 | 1/20 | 0.35 |
| ▸ | GNAO1 | P09471 | 1/20 | 0.35 |
| ▸ | GNAI1 | P63096 | 1/20 | 0.35 |
| ▸ | SIRT5 | Q9NXA8 | 2/20 | 0.34 |
| ▸ | ALB | P02768 | 1/20 | 0.33 |
| ▸ | FOLH1 | Q04609 | 1/20 | 0.33 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL19801989 | 0.90 | GLP1R (0.45) | GLP1RMEN1KMT2AFOLH1 | |
| SCHEMBL13640888 | 0.90 | GLP1R (0.43) | GLP1RDPP7MEN1KMT2AFAAH | |
| SCHEMBL12064338 | 0.87 | GLP1R (0.41) | GLP1RKDM4EMAPK1HIF1APAOX | |
| SCHEMBL15002710 | 0.85 | GLP1R (0.44) | GLP1RKDM4EMAPK1HIF1APAOX | |
| SCHEMBL14530622 | 0.85 | GLP1R (0.42) | GLP1RDPP7GNAI3GNAO1GNAI1 | |
| SCHEMBL23505676 | 0.84 | GLP1R (0.58) | GLP1RDPP7FAAHGNAI3GNAO1 | |
| SCHEMBL19049679 | 0.83 | GLP1R (0.52) | GLP1RFOLH1 | |
| SCHEMBL25651302 | 0.82 | GLP1R (0.45) | GLP1RKDM4EMAPK1HIF1APAOX | |
| SCHEMBL16285441 | 0.82 | KDM4E (0.56) | KDM4EMAPK1HIF1APAOXDPP7 | |
| SCHEMBL12118613 | 0.82 | GLP1R (0.42) | GLP1RKDM4EMAPK1HIF1APAOX |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20120283170-A1 | Acylated Exendin-4 Compounds | NOVO NORDISK A/S (DK) | 2012-11-08 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20120283170-A1 | Acylated Exendin-4 Compounds | GLP1R, VIP, IAPP | GLP1R 1/4885KDM4E 551/4885MAPK1 3876/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.